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In recent years, non-viral delivery systems for plasmid DNA have become particularly important. They 
can overcome the disadvantages of viral systems such as insertional mutagenesis and unpredicted 
immunogenicity. Some additional advantages of non-viral gene delivery systems are; good stability, low 
cost, targetability, delivery of a high amount of genetic materials. The aim of the study was to develop 
novel non-viral nanosystems suitable for gene delivery. Two formulations were developed for this purpose: 
water-in-oil microemulsion (ME) and solid lipid nanoparticles (SLN). The microemulsion was composed 
of Peceol, Tween 80, Plurol oleique, ethanol and water. The SLN was consisting of Precirol, Esterquat-1 
(EQ1), Tween 80, Lecithin, ethanol and water. Characterization studies were carried out by measuring 
particle size, zeta potential, viscosity and pH. TEM imaging was performed on SLN formulations. 
Protection against DNase I degradation was examined. Cytotoxicity and transfection efficacy of selected 
formulations were tested on L929 mouse fibroblast cells. Particle sizes of complexes were below 100 
nm and with high positive zeta potential. TEM images revealed that SLNs are spherical. The SLN:DNA 
complexes have low toxicity and good transfection ability. All results showed that the developed SLN 
formulations can be considered as suitable non-viral gene delivery systems. 
Keywords: Microemulsion. Solid lipid nanoparticle. DNA delivery. Transfection.
INTRODUCTION
Gene therapy using plasmid DNA molecules for 
specific diseases gained great importance in last decades. 
The main purpose of gene therapy is replacing diseased 
genes with new healthy ones. Selection of a proper 
gene delivery system is a very important issue when 
considering gene therapy because naked plasmid DNA 
(pDNA) is rapidly degraded following administration 
to the human body (Park et al., 2015). There are several 
methods developed for gene delivery. Generally, these 
methods can be divided into two main groups; 1) methods 
applying viral delivery systems, 2) methods applying 
non-viral delivery systems. Viral gene delivery systems 
have been the main choice during early gene therapy 
trials (Jomary et al., 1994; Edelstein et al., 2004). 
However, there were important drawbacks concerning 
the safety of these systems. For example, unpredicted 
immunogenicity and insertional mutagenesis are very 
dangerous adverse reactions that can develop after the 
treatment (Hackett et al., 2013; Solinís et al., 2014). 
Because of these complications, researchers developed 
non-viral gene delivery systems. Nowadays in gene 
delivery trials non-viral delivery systems are preferred 
over viruses because of their safety (Fornaguera et 
al., 2015). In addition, these systems possess other 
advantages such as good stability, targetability to specific 
sites, ability to deliver a high amount of materials, high 
therapeutic efficacy and low cost. However, non-viral 
vectors possess some disadvantages too. One of these 
disadvantages is that non-viral systems exhibit lower 
delivery efficacy than viral vectors (Mellott et al., 2013). 
Also, another important issue is their low transfection 
efficiency. Challenges in preserving the DNA intact 
during transportation in the biological fluids, low rate 
of endosomal escape and poor nuclear entry are known 
to contribute to the lower transfection efficiency of non-
viral gene delivery systems (Glinka, 2012).
In recent years, lipid nano-carriers such as 
liposomes, MEs and SLNs gained attention as therapeutic 
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gene delivery systems. SLNs have a particle size 
distribution varying from approximately 50 nm to 1000 
nm (Carrillo et al., 2013). Cationic SLNs are especially 
promising systems for gene delivery purposes (Severino 
et al., 2015). They are good alternatives to conventional 
formulations such as nanoemulsions and liposomes for 
gene delivery because of their good physical stability 
and biocompatibility (Jin, Kim, 2014). It is known that 
positively charged nanoparticles are most likely to be 
taken by cells via electrostatic interaction with negatively 
charged cell membranes (Jin, Kim, 2014; Remaut et al., 
2014). They are easily and cost effectively produced in 
large scale, and easy to generate. To transfect cells, these 
systems need a positive surface charge which can be 
provided by adding cationic lipids such as etylpyridinium 
chloride, cetyltrimethylammonium bromide (CTAB), 
dimethyldioctadecylammonium (DDAB), N-[1-(2,3-
dioleoyloxy)-propyl]-N,N,N-trimethylammonium methyl-
sulfate (DOTAP) and esterquat-1 which are some of the 
most widely used cationic lipids for obtaining cationic 
SLNs (Severino et al., 2015). The advantages of cationic 
SLNs are their good biocompatibility and low toxicity. 
These properties make them suitable for application by 
various routes (nasal, oral, ocular, topical, intravenous etc.) 
(Fàbregas et al., 2014). Another important advantage of 
SLNs is the ability to be produced from hot microemulsion 
intermediates. 
MEs are thermodynamically stable colloidal 
systems that form spontaneously under certain ratios of 
ingredients. MEs contain at least three main components; 
oil, emulsifier and water. MEs are easy to produce 
because of the self-assembling ability of the components. 
The most important property of MEs is to provide 
protection of encapsulated compounds (Chatzidaki et 
al., 2015). Water droplets formed in water-in-oil (W/O) 
microemulsions are good candidates for confining 
DNA. Because of DNA’s high water solubility, it can 
be easily incorporated into the inner water phase of a 
W/O microemulsion (Swami et al., 2008). The high 
viscosity of W/O MEs increases the stability and makes 
them suitable for topical application (Kajbafvala et al., 
2016; Callender et al., 2017). Chitosan is a widely used 
excipient in pharmaceutical formulations. It is regarded 
as non-toxic and biocompatible material (Shaji, Jain, 
Lodha, 2010) and is widely used as a DNA condensing 
cationic polymer. 
The first aim of this study was to develop and 
characterize a non-toxic solid lipid nanoparticle system 
employing hot o/w microemulsion dilution technique. 
The second aim was to prepare and characterize a w/o 
microemulsion formulation for plasmid DNA delivery. 
MATERIALS AND METHODS
Materials
Trizma base ,  Ethylenediaminete t raacet ic 
ac id  (EDTA) ,  sod ium dodecyl  su l fa te  (SDS) , 
Didecyldimethylammonium bromide (DDAB), Cetyl 
trimethylammonium bromide (CTAB), Tween 80, 
Chitosan (medium molecular weight), Phenol, 1-propanol 
and Span 80 were purchased from Sigma Aldrich 
GmbH (Steinheim, Germany). Soybean Lecithin (90% 
phosphatidylcholine) and Phosphate-buffered saline 
(PBS) tablets (pH: 7.4) were purchased from AppliChem 
GmbH (Darmstadt, Germany). XTT cell proliferation kit, 
Dulbecco’s Modified Eagle’s medium (DMEM), fetal 
bovine serum (FBS), trypsin, L-glutamine and penicillin-
streptomycin were purchased from Biological Industries 
(Beit-HaEmek, Israel). Precirol ATO-5, Labrafac PG, 
Labrafac Lipophile, Plurol Oleique CC, Lauroglycol 
FCC, Lauroglycol 90, Capryol PGMC, Labrafil M and 
Peceol were donated by Gattefossé (Cedex, France). 
DNase I (Enzyme I) was purchased from Biolabs (New 
England, USA). Ethanol was purchased from Merck KgaA 
(Darmstadt, Germany). Glacial acetic acid was purchased 
from Atabay Kimya (İstanbul, Turkey). Esterquat-1 
(N,N-di-(β-stearoylethyl)-N,N-dimethyl ammonium 
chloride) was purchased from Gerbu Biotechnik GmbH 
(Heidelberg, Germany). Agarose was purchased from 
Conda Laboratories (Madrid, Spain). Ethidium bromide 
was purchased from Fluka Chemie GmbH (Steinheim, 
Germany). pEGFP-C1 plasmid DNA and maxiprep 
plasmid DNA purification kit were purchased from 
Invitrogen (Carlsbad, CA, USA). DNA molecular weight 
standards (100bp and 1000bp) and DNase I (Enzyme II) 
were purchased from Fermentas, ThermoFischer Scientific 
(Waltham, Massachusetts, USA).
Plasmid DNA
pEGFP-C1 from Invitrogen (Carlsbad, CA, USA), 
which encodes green fluorescence protein (GFP) under 
CMV promoter, was used as the model plasmid in 
this study. pEGFP-C1 plasmid DNA was amplified in 
Escherichia coli JM109 strain and purified with Invitrogen 
maxiprep plasmid DNA purification kit (Carlsbad, CA, 
USA) according to manufacturer’s instructions. 
The integrity of the plasmid was assessed by 
restriction enzyme digestion, followed by agarose gel 
electrophoresis. 
The purity and the concentration of the plasmid 
were measured with nanoVette UV/Vis spectrophotometer 
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by measuring the absorbance of samples at 260/280 nm 
wavelengths. After isolation and purification, the plasmid 
DNA was diluted to 100 µg/mL and stored at -20 oC until 
use. 
Preparation of formulations
Preparation of SLN formulations
SLNs were produced by using hot microemulsification 
method. Microemulsions were obtained with Precirol 
ATO-5 as the solid lipid, Tween 80 and Soybean lecithin 
as hydrophilic and lipophilic surfactants, respectively, and 
ethanol as the cosurfactant (Cos). Tween 80 and lecithin 
were used at a ratio of 2:1 (wt/wt) and represented the 
surfactant (S) phase, and the S/Cos ratio was 1:2 (wt/wt). 
For obtaining cationic SLNs either Esterquat-1 or CTAB 
were included in the composition of formulations. 
Briefly, Precirol (100 mg), S/Cos (1440 mg), 
cationic lipid (56 mg) and water (2400 mg) were weighed 
and mixed with magnetic stirrer at 1500 rpm. The mixture 
was heated at 10 °C above the melting point of Precirol 
ATO-5 and a transparent hot microemulsion was obtained. 
Subsequently the microemulsion was rapidly transferred 
into 20 ml cold water and SLN dispersion was formed 
(Kotmakçı et al., 2016). 
Preparation of W/O ME formulation
Following materials were selected to construct 
pseudo-ternary phase diagram; Peceol (HLB: 1) as 
the oil phase, Plurol oleique (HLB: 6) and Tween 80 
(HLB: 15) as surfactants and Ethanol as co-surfactant. 
The purpose of generating phase diagram was to find 
optimum concentration ranges for formulation. Oil, S and 
Cos mixture which consist of predetermined amounts of 
the ingredients was titrated by adding 10 µL portions of 
water each time, and the appearance of the system was 
visually observed. The point where the appearance of the 
mixture turns to blurry was noted for each sample and 
used for the construction of the phase diagram. Titration 
was performed with constant stirring rate (300 rpm) at 
room temperature. Optimal ME existence areas were 
determined with phase diagrams drawn by means of a 
software developed at Ege University Faculty of Pharmacy 
(Ege, Karasulu, Güneri, 2004). 
Chitosan was used for providing cationic charge 
to MEs. Chitosan solution was prepared by dissolving 
chitosan with 1 % (v/v) glacial acetic acid (final chitosan 
concentration 0.3 % (wt/wt)). In order to obtain cationic 
ME, stable transparent w/o systems were selected from the 
phase diagrams and chitosan solution was added to these 
systems as the water phase.
Preparation of Cationic SLN:DNA complexes
To obtain the optimum complexation ratio, the 
following cationic SLN-to-plasmid DNA ratios were 
tested; 1:1, 2:1, 3:1, 4:1, 5:1, 7:1, 10:1 (v/v). Complexation 
was achieved at room temperature under stirring with 
vortex (300 rpm) for 30 minutes. Concentration of DNA 
working solution was 100 µg/mL.
Confinement of DNA in ME formulation
To confine the DNA in the ME formulation, first 
Chitosan:DNA complex was prepared. Chitosan solution 
(0.003 mg/mL) and DNA solution (100 µg/mL) were 
mixed at 1:1 (v/v) ratio and stirred with vortex (300 rpm) 
for 30 minutes at room temperature. Subsequently, the 
Chitosan:DNA complex dispersion was used as the water 
phase for the microemulsion. 
Characterization studies
Particle size distribution 
Particle size distribution of cationic SLNs was 
determined by dynamic light scattering using Malvern 
Zetasizer Nano ZS (Malvern Instruments, UK). Low 
volume disposable polystyrene cuvettes were used 
for size measurements. Formulations were diluted 10 
fold with ultrapure water and the measurements were 
performed at 25 °C. Particle size was measured in 
triplicate and mean zeta average diameter (±SD) was 
reported.
Zeta potential measurement
Zeta potential value of cationic SLNs was measured 
with Malvern Zetasizer Nano ZS (Malvern Instruments, 
UK). Standard zeta cuvettes were used and the working 
temperature was set to 25 °C during zeta potential 
measurements. Values were measured in triplicate and 
mean value (± SD) was presented.
pH measurement 
pH value of formulations was measured with 
SevenGo Duo SG 23 pH meter (Mettler Toledo Ohio, 
USA) at room temperature.
Refractive index and Viscosity measurements
Refractive index was measured with Krüss DR301-
95 refractometer (Hamburg, Germany), the viscosity was 
measured with Brookfield SV-10 vibrating viscometer 
(Brookfield Engineering Labs, Inc., Middleboro, MA). 
Measurements were carried out at room temperature. 
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TEM (Transmission Electron Microscopy) analysis
The morphology of formulations was investigated 
with FEI Tecnai G2 high contrast transmission electron 
microscope (FEI Co., USA). Approximately 10 µL 
samples were placed on carbon coated 200 mesh copper 
grids and allowed to dry overnight at room temperature. 
Observations were carried out at 120 kV.
SDS-induced DNA release study
The release of DNA from the SLNs was assessed 
with agarose gel electrophoresis. SDS was added 
immediately after complex formation. Following 5 
minutes incubation at 25°C, samples were loaded on 1% 
agarose gel for electrophoresis. Two SLN:DNA ratios 
were tested - 1:1 and 1:2 (v/v). Optimal SDS amount was 
determined by applying the following SDS percentages to 
gel; 0.5, 1, 1.5, 2, 2.5. 
DNase I protection study
Two different commercial DNase I enzymes were 
used for this study (Fermentas, ThermoFischer Scientific 
(Waltham, Massachusetts, USA) and Biolabs, (New 
England, USA)). SLN:DNA ratios were 1:1 and 1:2 (v/v). 
0.4 IU DNase I was applied per each 1 µg DNA. 
After complex formation DNase I was added and 
incubated for 30 minutes at 37oC in a heating water bath. 
Subsequently, SDS (%1) was added to release the DNA for 
analysis and incubated as described above. Samples were 
loaded to %1 agarose gel. Electrophoresis was carried out 
for 1 hour at 100 volts. 
Cell culture
All cell culture studies were carried out on L929 
mouse fibroblast cell line, as it is a commonly used cell 
line. Formulations were freshly prepared and SLN:DNA 
complexes were obtained immediately before the 
application.
Cytotoxicity study
Cytotoxicity of formulations was estimated by 
measuring cell viability with XTT cell proliferation 
assay. For this purpose, cells were inoculated in 96 
well plates at a density of 6x103 cells/well. Plates were 
incubated for 24 h at 37 oC in a humidified atmosphere 
(%5 CO2) to allow the cell to adhere to the wells. After 
24 hours, cells were treated with SLNs and SLN:DNA 
complexes at the following doses; 3, 5, 7, 10, 15, 20 µL/
well. Each dose was applied to the wells in a final volume 
of 100 μL. After another 24 hours of incubation, cells 
were washed with PBS and fresh medium was added. 
50 µL of XTT solution was added to each well. After 
150 minutes of incubation, absorbance was measured 
at 450-630 nm using Varioskan Flash microplate reader 
(ThermoFisher Scientific, USA). Untreated cells were 
used as control group.
Transfection ability
Doses with low toxicity (3 µL and 5 µL) were used 
in transfection studies. Transfection ability was evaluated 
under a fluorescence microscope (Olympus, Japan). In 
order to evaluate the transfection ability considering 
vitality, cells were stained with DAPI (4’,6-diamidino-
2-phenylindole) for 1-5 min after performing the 
transfection. 
Stability
SLNs in suspension form were evaluated for change 
in particle size, zeta potential and PDI with Nicomp 380 
ZLS (Particle Sizing Systems, USA) for two months. ME 
formulation was observed visually for clarity and phase 
separation for two years. Formulations were stored at room 
temperature. 
Statistical analysis
All results are presented as mean ±SD of at least 
three measurements. Statistical analysis was performed 
using Student’s t-test and analysis of variance (ANOVA). 
A “p” value of less than 0.05 was considered significant.
RESULTS
ME formulation
As shown in Figure 1, pseudo ternary phase 
diagram was constructed by titration procedure with 
water. Optimal S:Cos ratio was 1:1 (wt/wt). The selected 
microemulsion formulation is presented as a black point 
on the microemulsion area and consists of 28 % Peceol, 
21 % Plurol Oleique, 7 % Tween 80, 28 % ethanol, and 
16 % water. 
DNA-SLN complexation
Figure 2 shows the agarose gel photograph of 
samples tested for complexation at different SLNEQ1:DNA 
ratios.
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In this preliminary study, it was seen that increasing SLN 
ratio from 1:1 to 2:1 has no significant effect on DNA 
release. It was also seen that 1% SDS will be appropriate 
for further studies. We aimed to compare cationic 
SLNs prepared with different cationic lipids in terms of 
complexation and SDS induced DNA release. According 
to the (Figure 4) lane 6 and lane 7, both formulations 
released DNA properly in the presence of 1% SDS.
Figure 5 shows the agarose gel photograph of 
SLNEQ1 for DNase I protection study. Lane 2 is the 
negative control (untreated plasmid). According to 
lane 2, uncomplexed DNA was fully digested by the 
DNase I. Lanes 3-10, show the protection of SLNEQ1 
formulation against two different nuclease enzymes at 
FIGURE 1 - Pseudo ternary phase diagram obtained with peceol, 
plurol oleique, T80 and ethanol. S/Cos ratio: (1:1). Grey area 
represents W/O microemulsion formation area. Black dot 
represents the selected W/O microemulsion
FIGURE 2 - Agarose gel photograph showing SLNEQ1:DNA 
complexation. Lane 1: GeneRuler 1 kb DNA ladder; Lane 
2: SLN; Lane 3: naked DNA as control; Lane 4: SLN:DNA 
1:1; Lane 5: SLN:DNA 2:1; Lane 6: SLN:DNA 3:1; Lane 7: 
SLN:DNA 4:1; Lane 8: SLN:DNA 5:1; Lane 9: SLN:DNA 7:1; 
Lane 10: SLN:DNA 10:1.
TABLE I - Particle size, PDI and Zeta potential values of SLN formulations (n=3)
Formulation Particle Size (nm) (±SD) PDI (±SD) Zeta Potential (mV) (±SD)
SLNCTAB 44.9 (±0.77) 0.394 (±0.011) 44.000 (±0.16)
SLNEQ1 104.7 (±1.25) 0.309 (±0.004) 47.333 (±2.32)
SLNCTAB:DNA 72.9 (±2.00) 0.266 (±0.001) 45.933 (±3.26)
SLNEQ1:DNA 98.9 (±0.28) 0.287 (±0.003) 41.567 (±0.32)
SD: standard deviation, SLNCTAB: SLN formulation prepared with CTAB as the cationic lipid, SLNEQ1: SLN formulation prepared 
with EQ1 as the cationic lipid.
Characterization of obtained microemulsion, 
SLNs and SLN:DNA complexes
pH values of SLNEQ1 and ME formulations were 
determined as 3.9 and 3.4, respectively. Viscosity and 
refractive index values of ME formulation were obtained 
as 36 cP and 1.42, respectively. Table I shows the particle 
size, PDI and zeta potential values of SLN formulations 
and SLN:DNA complexes. Figure 3 shows the intensity-
size distribution of SLN:DNA formulations.
SDS induced DNA release and protection against 
DNase I degradation
For SDS induced DNA release study, SLN:DNA 
complexes were prepared in two ratios; 1:1 and 2:1 (v/v). 
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two different SLNEQ1:DNA ratios (1:1 and 1:2 (v/v)). 
DNase I protection study results of SLNCTAB were not 
given because the formulation was determined to be 
cytotoxic on L929 cells. 
Cytotoxicity and transfection of L929 cells
Cytotoxici ty  and t ransfect ion abi l i t ies  of 
formulations were tested on L929 mouse fibroblast cells. 5, 
7, 10, 15, 20 µL/well doses were tested. Cell viability after 
treatment with the ME, ME:DNA, SLNs and SLN:DNA 
formulations were presented in Figure 6. 
Figure 7 shows the transfection ability of selected 
formulations. Blue colored images indicate DAPI staining. 
DAPI staining shows living cells under an inverted 
microscope. Green color indicates fluorescence from GFP 
expressed in the cells. 
Stability
ME formulation was observed visually for 2 
years. No turbidity or phase separation was determined 
during this period. The formulation was stored in a dry 
atmosphere in the dark in sealed glass vials. The storage 
temperature was 25 °C. 
The SLNEQ1 formulation in suspension form was 
observed for 6 weeks for particle size and PDI change. 
The formulation was stored as described for ME. At the 
end of the 45th day, stability study was terminated because 
of turbidity formation. Measurement results are presented 
in Table II. 
TEM analysis
ME formulation could not be visualized because of 
its high oil content. SLNEQ1 and SLNEQ1:DNA formulations 
were imaged with transmission electron microscope. TEM 
micrographs can be seen in Figure 8. The morphology of 
SLNs appeared to be spherical (Figure 8A). On the other 
hand, the morphology of SLNEQ1:DNA complexes are 
observed to be granular (Figure 8B). 
DISCUSSION 
Microemulsion formulations have advantages for 
FIGURE 3 - Intensity-size distribution graphs of SLN:DNA 
complexes.
FIGURE 4 - Comparison of SLNEQ1 and SLNCTAB formulations 
for complexation and SDS induced DNA release abilities. 
Lane 1: naked plasmid DNA as control; Lane 2: SLNEQ1; 
Lane 3: SLNCTAB; Lane 4: SLNEQ1:DNA (1:1); Lane 5: 
SLNCTAB:DNA(1:1); Lane 6: SLNEQ1:DNA treated with %1 SDS; 
Lane 7: SLNCTAB:DNA treated with %1 SDS.
FIGURE 5 - DNase I protection of SLNEQ1:DNA complexes. Lane 
1: naked DNA as control; Lane 2: naked DNA+ Enzyme I as 
positive control; Lane 3: SLNEQ1:DNA 1:1; Lane 4: SLNEQ1:DNA 
1:2; Lane 5: SLNEQ1:DNA 1:1; Lane 6: SLNEQ1:DNA 1:2; 
Lane 7: SLNEQ1:DNA 1:1; Lane 8: SLNEQ1:DNA 1:2; Lane 9: 
SLNEQ1:DNA 1:1; Lane 10: SLNEQ1:DNA 1:2; Lanes 3,4,7,8 
treated with Enzyme I; Lanes 5,6,9,10 treated with Enzyme II.
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DNA delivery because of their transparent appearance, 
spontaneous formation and thermodynamical stability. The 
optical density of formulations can provide indications 
about the reproducibility of formulations. Monitoring 
the solubilization is another advantage for transparent 
formulations (Ulrich, 2002). Besides, cationic materials 
(in this case chitosan), that facilitate DNA encapsulation 
in microemulsions, can easily be incorporated into the 
formulation (Lee et al., 2010). Another advantage of 
W/O microemulsion is confining and protecting DNA in 
its inner phase (Baroli et al., 2000). In this study, Plurol 
oleique was selected as a lipophilic surfactant because of 
its ability to create transparent ME systems. Employing 
Plurol oleique, the HLB value of the system was decreased 
dramatically. To adjust HLB value which is appropriate 
for w/o ME system, Tween 80 was used as a hydrophilic 
surfactant. The location of selected formulation in ME 
area can be seen in Figure 1. HLB value of ME system 
was calculated as 5.63. The viscosity of ME was 36 cP, 
which is an appropriate value for topically administered 
formulations. It was previously shown that increasing 
viscosity values renders MEs suitable for topical 
application.
SLNs are good delivery tools for genetic materials. 
Factors such as the protection of genetic materials from 
degradation and efficient delivery potential into cells 
make SLNs a perfect choice for gene delivery purposes 
(Torrecilla et al., 2015). In this study, Precirol ATO5 was 
FIGURE 6 - Cell viability after treatment with formulations at different doses.
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used as the oil phase for SLN formulation. Ethanol was 
used as the co-surfactant, because of its ability to easily 
dissolve lecithin and its non-toxic characteristics. For an 
efficient transfection, the particle size of formulations 
should be approximately 100 nm because transfection 
activity strongly depends on the cellular uptake (Ulrich, 
2002). SLNCTAB (44.9 nm) and SLNEQ1 (104.7 nm) 
formulations have a suitable particle size for DNA 
delivery. PDI values of SLN formulations are 0.3 which is 
acceptable for monodisperse systems (Gaur et al., 2014). 
SLN systems with zeta potential greater than ±30 mV can 
be considered as stable systems (Ulrich, 2002; Carrillo et 
al., 2013). As shown in Table I the zeta potential values 
of developed formulations are sufficiently high, so these 
formulations can be considered stable systems (Carrillo 
et al., 2013; Fàbregas et al., 2014). 
Considering its small particle size, SLNCTAB 
appeared as a suitable formulation. However, it was highly 
cytotoxic. On the other hand, the cytotoxicity of SLNEQ1 
was more acceptable in comparison with that of SLNCTAB. 
As shown in Figure 6, SLNEQ1:DNA complex exhibited 
approximately 80% cell viability at the dose 7 µL/well, 
which is suitable for cell culture studies. According 
to previous studies it is generally accepted that a zeta 
potential greater than +25 mV is appropriate for SLNs 
forming complexes with DNA (Fàbregas et al., 2014). 
SLNEQ1 showed high positive zeta potential (+47.3 mV), 
which is essential for the formation of stable complexes 
with DNA. Determining the optimum SLN:DNA ratio 
provides insights about maximum DNA amount that can 
be loaded to a given formulation (Fàbregas et al., 2014). 
From Figure 2, it can be seen that the ratio of 1:1 (SLN-
to-DNA) is optimal. At this complexation ratio, all DNA 
molecules are entrapped by the complex and show no 
FIGURE 7 - Transfection ability of formulations (A and 
B: ME:DNA 5 µL, C and D: SLNEQ1:DNA 3 µL, E and F: 
SLNEQ1:DNA 5 µL, G and H: Control (naked DNA+L929 cells)). 
A,C,E,G images represent DAPI staining; B,D,F,H images 
represent fluorescence visualization.
FIGURE 8 - TEM imaging of SLNEQ1(A) and SLNEQ1:DNA (B).
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mobility during electrophoresis. As can be seen from the 
lanes 6-10 in Figure 2, the complex enters the gel at the 
opposite side. Considering this fact, it can be suggested 
that at higher SLN-to-DNA ratios, the complex becomes 
more positively charged and its movement is observed to 
be towards the cathode. 
As it can be seen in Figure 3 both SLN:DNA 
complexes have narrow size distributions. Comparison of 
SLNCTAB and SLNEQ1 can be seen in Figure 4. Gel image 
confirms the zeta potential measurements. According to 
Figure 4 (lanes 4 and 5), CTAB contributed to production 
of cationic SLNs with higher positive charge than EQ1. 
Lanes 6 and 7 indicate that both SLNEQ1 and SLNCTAB are 
able to release DNA in the presence of SDS. 
In order to obtain more reliable results, two different 
commercial enzymes were used for DNase I protection 
assay. According to lane 2 in Figure 5, naked DNA was 
completely digested by DNase I enzyme. DNA is in 
supercoiled form and only small amounts of nick DNA 
are observed in the wells loaded with the complexes. 
According to these results, all SLNEQ1:DNA complexes 
are protecting DNA from enzymatic degradation. 
SLNCTAB:DNA results were not given because of its poor 
cytotoxicity results. 
Agarose gel electrophoresis studies couldn’t be 
performed on ME formulations due to their high content 
of oil which makes them impossible to load on agarose 
gel wells. 
The cytotoxicities of all formulations were dose 
dependent except SLNCTAB formulations (Figure 6). The 
ME showed approximately 60% viability for the doses 
5, 7 and 10 µL/well. The cytotoxicity decreases when 
DNA complexed with ME. ME:DNA formulation showed 
approximately 80% viability for the doses 3 and 5 µL/
well (significantly higher than ME, p<0.0025). At higher 
doses, cell viability decreased drastically. Therefore, 
doses higher than 5 µL/well were accepted as cytotoxic 
and were not tested for the transfection experiments. 
SLNEQ1:DNA complexes showed 80% cell viability at 
the dose 7 µL/well, so 3,5,7 µL/well doses were safely 
used for transfection studies. Moreover, the viability of 
cells treated with SLNEQ1:DNA at the dose 5 µL/well 
was not significantly reduced as compared to the control 
group (p=0.2867). SLNCTAB showed high toxicity on L929 
cells at all tested doses. Therefore, this formulation was 
not included in any further experiment. DAPI binds to 
A-T rich regions of DNA and shows living cells in blue 
color. Merging DAPI-stained and GFP filter micrographs 
provides information about the transfection ability. 
As shown in Figure 7 A and B, a small number 
of transfected cells were observed with ME:DNA. ME 
formulation contains DNA in its inner phase. Because 
of the fact that the volume of the inner phase is very low 
(%16), the ME system contains a small amount of DNA 
(0.04 µg DNA in 5 µL dose). However, SLN 5 µL dose 
contains 0.25 µg DNA in 1:1 (v/v) complexation rate. 
As shown in Table II, the particle size of SLNEQ1 
decreased slightly during the storage period. However, 
this decrease is not an abnormal situation exactly. Related 
literature shows that SLNs’ particle sizes could decrease 
during storage nearly to 30-40% (del Pozo-Rodríguez 
et al., 2009). After 45 days of storage, formulations’ 
appearance became cloudy. That was a sign that SLNs’ 
integrity was breaking down. Therefore, stability 
measurements were terminated at this point (Bose, 
Michniak-Kohn 2013; Dolatabadi et al., 2014). The 
stability of ME was monitored by visual inspection for 2 
years. No change in the appearance was observed during 
this period.
According to TEM images, the shape of SLNEQ1 is 
spherical and the size of particles is about 50 nm (Figure 
8 A). As shown in Figure 8 panel B, pDNA is successfully 
complexed with SLNEQ1 and the morphology of the 
complex appears wrinkled. TEM images reflects particle 
size more directly than the DLS measurements (Lee et 
al., 2013).
CONCLUSIONS 
In conclusion, two non-viral DNA carrier systems 
were developed and evaluated for plasmid DNA delivery. 
Because of its high viscosity, microemulsion system 
is suitable for topical application. Cytotoxicity of 
formulations can be adjusted by screening for safe doses 
as evidenced by cytotoxicity studies. In this study, at 
lower non-toxic doses SLNEQ1:DNA complexes provided 
good transfection efficiency with EGFP-encoding plasmid 
DNA. The SLN formulation described in this study is 
suitable for investigating novel treatment modalities for 
various disease models by replacing EGFP-encoding 
plasmid DNA with therapeutic gene-encoding plasmids. 
TABLE II - Stability of SLNEQ1 at room temperature for 
1.5 months
Day Particle Size (nm) Polidispersity Index
1 87.3 0.238
15 96.8 0.203
30 93.8 0.241
45 77.8 0.251
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